Celgene Corp (CELG)

CELG (NASDAQ:Drugs)
$86.65
neg -0.50
-0.57%
Today's Range: 86.20 - 87.85 | CELG Avg Daily Volume: 4,881,000
Last Update: 08/01/14 - 4:00 PM EDT
Volume: 4,981,963
YTD Performance: 3.16%
Open: $86.61
Previous Close: $87.15
52 Week Range: $65.76 - $90.50
Oustanding Shares: 799,510,100
Market Cap: 35,314,361,117
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 16 18 18 21
Moderate Buy 0 1 1 2
Hold 4 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.40 1.39 1.39 1.31
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 51.06
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
51.06 50.90 28.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
18.56% 18.68% 193.93%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.90 0.79 0.21
Net Income -0.40 0.65 0.18
EPS 2.00 0.84 0.22
Earnings for CELG:
EBITDA 2.35B
Revenue 6.49B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.82 $0.87 $3.18 $4.43
Number of Analysts 3 3 2 3
High Estimate $0.85 $0.91 $3.18 $4.94
Low Estimate $0.79 $0.85 $3.17 $4.09
Prior Year $0.69 $0.67 $2.68 $3.18
Growth Rate (Year over Year) 17.51% 30.83% 18.47% 39.53%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Jul 30, 2014 | 11:11 AM EDT

Where what the Fed does allegedly determines everything.

bullishCelgene estimates, target increased at Credit Suisse

Jul 25, 2014 | 8:08 AM EDT

CELG estimates were raised through 2016, Credit Suisse said. Company boosted its guidance. Outperform rating and new $113 price target. 

By

Jim Cramer

 | Jul 24, 2014 | 3:05 PM EDT

Boeing, Celgene and Qualcomm have big upside, though their stocks are lagging.

By

Jim Cramer

 | Jul 23, 2014 | 1:54 PM EDT

McDonald's and GlaxoSmithKline are fighting against major turns of the tide.

By

Jim Cramer

 | Jul 17, 2014 | 7:10 AM EDT

If you're worried about these moves, it's time to cash out.

By

Ed Ponsi

 | Jul 16, 2014 | 12:00 PM EDT

There's a great entry point in Celgene at $84.

By

Jim Cramer

 | Jul 15, 2014 | 2:15 PM EDT

If you don't like speculation, just hike the margin requirement.

By

Jim Cramer

 | Jul 8, 2014 | 4:08 PM EDT

The lower risk stocks have been providing consistent returns.

By

Jim Cramer

 | Jul 1, 2014 | 7:06 PM EDT

Be bitter about the soccer match, not the latecomers and the naysayers. 

By

Jim Cramer

 | Jul 1, 2014 | 1:54 PM EDT

Another quarter, another run to record highs.

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Bef...
Last year saw the MC NYSE oscillator hit -300 on about five occasions, and each time a mas...
If you are in the NYC area, Bob Lang and I will be in town this Monday and Tuesday night. ...
There are no signals in IWM....Still watching zone 2 in WYNN for a potential entry. The up...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.